StockMarketWire.com - Healthcare investor Syncona said an indicative pricing range for an initial public offering of portfolio company Freeline Therapeutics would represent an increase in the value of its current shareholding.
Freeline Therapeutics said the indicative pricing range for the offering of American depository shares was $16-to-$18.
That would represent an increase in value of Syncona's current shareholding in Freeline of £31.6m-to-£58.2m.
Syncona said it had indicated an interest in purchasing ADSs in the offering, subject to agreement with the underwriters.
At 1:16pm: [LON:SYNC] Syncona Limited share price was +5.25p at 243.25p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.